倍他米松转化技术研究进展  

Research Progress on Conversion Technology of Betamethasone

作　　者：阳飞[1] 邓玉宁 谭小焱 谭焕卿 Yang Fei;Deng Yu’ning;Tan Xiaoyan;Tan Huanqing(Hubei University of Technology Engineering and Technology College,Wuhan 430068,China)

机构地区：[1]湖北工业大学工程技术学院,湖北武汉430068

出　　处：《广东化工》2020年第24期57-59,共3页Guangdong Chemical Industry

基　　金：校教研项目X2017006。

摘　　要：倍他米松(Betamethasone)属于糖皮质激素类药物,具有抗炎、抗过敏和抑制免疫等多种药理作用。国内外研究报道倍他米松合成主要是基于剑麻皂素、番麻皂素、薯蓣皂素、甾类化合物中间体等原料经过化学或微生物转化合成,文章对主要转化技术及其特点进行了简要论述。Betamethasone that belongs to glucocorticoid drugs has anti-inflammatory, anti-allergic and immune suppression and other pharmacological effects. Domestic and foreign research reports that betamethasone can be synthesized mainly by chemical methods or biotransformation from the raw material such as tigogenin, hecogenin, diosgenin and steroid compounds, and so on. This paper expounds main conversion technology of betamethasone and its characteristics.

关 键 词：倍他米松 剑麻皂素 番麻皂素 薯蓣皂素 甾类化合物 

分 类 号：O624.2[理学—有机化学]